Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

OBJECTIVE: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with moderate‐to‐severe systemic lupus erythematosus (SLE). METHODS: Patients (n = 305) were randomized to receive...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Arthritis Rheumatol
Main Authors: Furie, Richard, Khamashta, Munther, Merrill, Joan T., Werth, Victoria P., Kalunian, Kenneth, Brohawn, Philip, Illei, Gabor G., Drappa, Jorn, Wang, Liangwei, Yoo, Stephen
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Systemic Lupus Erythematosus
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5299497/
https://ncbi.nlm.nih.gov/pubmed/28130918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.39962
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares